Literature DB >> 25252033

Elevation of Serum Levels of Advanced Glycation End Products in Patients With Non-B or Non-C Hepatocellular Carcinoma.

Hiromi Kan1, Sho-ichi Yamagishi2, Ayako Ojima2, Kei Fukami3, Seiji Ueda3, Masayoshi Takeuchi4, Hideyuki Hyogo1, Hiroshi Aikata1, Kazuaki Chayama1.   

Abstract

BACKGROUND: The prevalence of non-B or non-C hepatocellular carcinoma (NBNC-HCC) has been increasing all over the world. Advanced glycation end products (AGE) play a role in the pathogenesis of alcoholic liver injury or nonalcoholic steatohepatitis (NASH).
METHODS: We examined here whether serum levels of AGE were elevated in NBNC-HCC patients compared with NASH subjects without HCC and investigated which anthropometric and clinical variables were independent determinants of AGE.
RESULTS: Ninety NBNC-HCC, 56 NASH, and 27 control subjects underwent a complete history and physical examination, determination of blood chemistries, including AGE levels. Serum levels of AGE were significantly higher in NBNC-HCC patients compared with NASH and control subjects [9.1 ± 2.7, 5.2 ± 1.7, 3.5 ± 1.2 (U/ml), respectively, P < 0.05]. Univariate analysis showed that AGE levels were associated with male (P < 0.05), age (P < 0.01), aspartate aminotransferase (P < 0.05), γ-glutamyl transpeptidase (GGT) (P < 0.01), HDL-cholesterol (inversely, P < 0.01), fasting plasma glucose (P < 0.01), and HbA1c (P < 0.05). By the use of multiple stepwise regression analysis, age, GGT, and HDL-cholesterol (inversely) remained significant and were independently related to AGE levels (R(2) = 0.406).
CONCLUSION: The present results suggest that AGE might be involved in the pathogenesis of NBNC-HCC, thereby being a biomarker that could discriminate NBNC-HCC from NASH.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  AGE; NASH; Non-B or non-C hepatocellular carcinoma

Mesh:

Substances:

Year:  2014        PMID: 25252033      PMCID: PMC6807017          DOI: 10.1002/jcla.21797

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  41 in total

1.  Clinicopathologic characteristics of patients with non-B non-C hepatitis virus hepatocellular carcinoma after hepatectomy.

Authors:  Masaki Kaibori; Morihiko Ishizaki; Kosuke Matsui; A-Hon Kwon
Journal:  Am J Surg       Date:  2012-05-15       Impact factor: 2.565

Review 2.  Epidemiology of viral hepatitis and hepatocellular carcinoma.

Authors:  Hashem B El-Serag
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

3.  Evaluation of tumour necrosis factor-alpha, soluble P-selectin, gamma-glutamyl transferase, glutathione S-transferase-pi and alpha-fetoprotein in patients with hepatocellular carcinoma before and during chemotherapy.

Authors:  M I Morsi; A E Hussein; M Mostafa; E El-Abd; N A Abd El-Moneim
Journal:  Br J Biomed Sci       Date:  2006       Impact factor: 3.829

4.  The metabolic syndrome as a predictor of nonalcoholic fatty liver disease.

Authors:  Masahide Hamaguchi; Takao Kojima; Noriyuki Takeda; Takayuki Nakagawa; Hiroya Taniguchi; Kota Fujii; Tatsushi Omatsu; Tomoaki Nakajima; Hiroshi Sarui; Makoto Shimazaki; Takahiro Kato; Junichi Okuda; Kazunori Ida
Journal:  Ann Intern Med       Date:  2005-11-15       Impact factor: 25.391

5.  Recent trend of clinical features in patients with hepatocellular carcinoma.

Authors:  Yuko Nagaoki; Hideyuki Hyogo; Hiroshi Aikata; Mio Tanaka; Noriaki Naeshiro; Takashi Nakahara; Yoji Honda; Daisuke Miyaki; Tomokazu Kawaoka; Shintaro Takaki; Akira Hiramatsu; Koji Waki; Michio Imamura; Yoshiiku Kawakami; Shoichi Takahashi; Kazuaki Chayama
Journal:  Hepatol Res       Date:  2011-12-13       Impact factor: 4.288

6.  Cancer statistics, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

7.  Role of advanced glycation end products (AGEs) in osteoporosis in diabetes.

Authors:  Sho-ichi Yamagishi
Journal:  Curr Drug Targets       Date:  2011-12       Impact factor: 3.465

8.  Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study.

Authors:  Yuichiro Eguchi; Hideyuki Hyogo; Masafumi Ono; Toshihiko Mizuta; Naofumi Ono; Kazuma Fujimoto; Kazuaki Chayama; Toshiji Saibara
Journal:  J Gastroenterol       Date:  2012-02-11       Impact factor: 7.527

9.  Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells.

Authors:  Keiko Iwamoto; Keishi Kanno; Hideyuki Hyogo; Sho-Ichi Yamagishi; Masayoshi Takeuchi; Susumu Tazuma; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2008-05-06       Impact factor: 7.527

10.  Acetaldehyde-derived advanced glycation end-products promote alcoholic liver disease.

Authors:  Nobuhiko Hayashi; Joseph George; Masayoshi Takeuchi; Atsushi Fukumura; Nobuyuki Toshikuni; Tomiyasu Arisawa; Mikihiro Tsutsumi
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

View more
  13 in total

Review 1.  Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma.

Authors:  Jun-Ichi Takino; Kentaro Nagamine; Takamitsu Hori; Akiko Sakasai-Sakai; Masayoshi Takeuchi
Journal:  World J Hepatol       Date:  2015-10-18

Review 2.  Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies.

Authors:  Masayoshi Takeuchi; Jun-Ichi Takino; Akiko Sakasai-Sakai; Takanobu Takata; Tadashi Ueda; Mikihiro Tsutsumi; Hideyuki Hyogo; Sho-Ichi Yamagishi
Journal:  World J Hepatol       Date:  2014-12-27

3.  Dietary intake of advanced glycation endproducts and risk of hepatobiliary cancers: A multinational cohort study.

Authors:  Ana-Lucia Mayén; Elom K Aglago; Viktoria Knaze; Reynalda Cordova; Casper G Schalkwijk; Karl-Heinz Wagner; Krasimira Aleksandrova; Veronika Fedirko; Pekka Keski-Rahkonen; Michael F Leitzmann; Verena Katzke; Bernard Srour; Matthias B Schulze; Giovanna Masala; Vittorio Krogh; Salvatore Panico; Rosario Tumino; Bas Bueno-de-Mesquita; Magritt Brustad; Antonio Agudo; María Dolores Chirlaque López; Pilar Amiano; Bodil Ohlsson; Stina Ramne; Dagfinn Aune; Elisabete Weiderpass; Mazda Jenab; Heinz Freisling
Journal:  Int J Cancer       Date:  2021-04-25       Impact factor: 7.316

Review 4.  Toxic AGE (TAGE) Theory for the Pathophysiology of the Onset/Progression of NAFLD and ALD.

Authors:  Masayoshi Takeuchi; Jun-Ichi Takino; Akiko Sakasai-Sakai; Takanobu Takata; Mikihiro Tsutsumi
Journal:  Nutrients       Date:  2017-06-20       Impact factor: 5.717

Review 5.  Prevention of protein glycation by natural compounds.

Authors:  Izabela Sadowska-Bartosz; Grzegorz Bartosz
Journal:  Molecules       Date:  2015-02-16       Impact factor: 4.411

Review 6.  RAGE is a Potential Cause of Onset and Progression of Nonalcoholic Fatty Liver Disease.

Authors:  Kamyar Asadipooya; Kamran B Lankarani; Rishi Raj; Mohammadreza Kalantarhormozi
Journal:  Int J Endocrinol       Date:  2019-09-18       Impact factor: 3.257

Review 7.  Serum Levels of Toxic AGEs (TAGE) May Be a Promising Novel Biomarker for the Onset/Progression of Lifestyle-Related Diseases.

Authors:  Masayoshi Takeuchi
Journal:  Diagnostics (Basel)       Date:  2016-06-07

Review 8.  The Role of Glyoxalase-I (Glo-I), Advanced Glycation Endproducts (AGEs), and Their Receptor (RAGE) in Chronic Liver Disease and Hepatocellular Carcinoma (HCC).

Authors:  Marcus Hollenbach
Journal:  Int J Mol Sci       Date:  2017-11-20       Impact factor: 5.923

9.  Impact of intracellular glyceraldehyde-derived advanced glycation end-products on human hepatocyte cell death.

Authors:  Akiko Sakasai-Sakai; Takanobu Takata; Jun-Ichi Takino; Masayoshi Takeuchi
Journal:  Sci Rep       Date:  2017-10-27       Impact factor: 4.379

10.  Identification of Antiglycative Compounds in Japanese Red Water Pepper (Red Leaf Variant of the Persicaria hydropiper Sprout).

Authors:  Wakako Takabe; Taiki Yamaguchi; Hideharu Hayashi; Natsuhiko Sugimura; Masayuki Yagi; Yoshikazu Yonei
Journal:  Molecules       Date:  2018-09-11       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.